1825P Prevalence of cancer among e-cigarette smokers compared to non-smokers: A retrospective cross-sectional survey study of NHANES-CDC

A Chidharla
R Rabbani
K Agarwal
S Abdelwahed
R Bhandari

See next page for additional authors

Follow this and additional works at: https://scholarlycommons.henryford.com/internalmedicine_mtgabstracts
Authors
A Chidharla, R Rabbani, K Agarwal, S Abdelwahed, R Bhandari, P S. Manaktala, A Singh, K Patel, P Singh, D Mehta, P Malik, U Patel, Shreejith Pillai, and T Koritala
GENERAL INTEREST

1824P  Attitudes, knowledge, and need for education about LGBTQ patients with cancer: A survey by the ESMO/SIOPE AYA with cancer Working Group


1Department of Oncology, University Hospital of Larissa, Larissa, Greece; 2Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; 3Medical Oncology Department, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia; 4Department of Oncology for Child and Adolescent, Gustave Roussy Cancer Campus, Villejuif, France; 54th Department of Medical Oncology and Clinical Trials Unit, Henry Dunant Hospital, Athens, Greece; 6Department of Scientific Programme Coordination, European Society for Paediatric Oncology (SIOPe), Brussels, Belgium; 7Zentrum für Klinische Onkologie und Familienmedizin Philipp Staeckes-Klinikum, Olaphospital, Stuttgart, Germany; 8Leeds Institute of Medical Research, School of Medicine University of Leeds, Leeds, UK; 9Scientific and Medical Division, European Society for Medical Oncology (ESMO), Lugano, Switzerland; 10Division of Gynecoologic Oncology, European Institute of Oncology IRCCS, Milan, Italy

Background: Sexual and gender minorities [lesbian, gay, bisexual, transgender, and queer/questioning (LGBTQ)] is a diverse group that is at risk for receiving disparate cancer care. A survey of the European Society for Medical Oncology (ESMO) and the European Society for Paediatric Oncology (SIOPe) membership showed limited interest in LGBTQ patients with cancer.

Methods: A link to an online survey was sent to the members of ESMO and SIOP Europe to measure attitudes and knowledge about LGBTQ health, and clinical practices. Results were analyzed by using descriptive analyses.

Results: Among the 672 respondents, there was high agreement regarding the importance of knowing the gender identity as perceived by the patient (75%) and sex at birth (78%), which was contrasted by lower agreement (54%) regarding the importance of knowing sexual orientation. However, the majority doesn’t ask sex at birth and gender identity during first visit (64% and 58% respectively). Only a minority of the respondents considered themselves well informed regarding gays/lesbians and transgender patients’ health (44 and 25% respectively), and psychosocial needs (34%). Questions about cancer risk in relation to sexual orientation and in those who identify themselves as a different gender compared to risk estimated based on their gender at birth yielded mixed responses. There was high interest in receiving education regarding the unique health needs of LGBTQ patients (73%), which was considered as a core skill for all cancer specialists by 72%. For most of the questions no significant differences were noted among those who defined themselves as heterosexual, gays/lesbians or bisexual.

Conclusions: This is the largest, to our knowledge, and the first among European specialists survey, addressing attitude, knowledge and interest for further education needs about LGBTQ patients with cancer. A lack in knowledge about clinical and psychosocial issues was revealed, as well as high interest in receiving LGBTQ-specific education and clinical practice guidelines.

Legal entity responsible for the study: European Society for Medical Oncology (ESMO), European Society for Paediatric Oncology (SIOPe).

Disclosure: E. Salustros: Financial Interests, Personal, Advisory Board: Roche Hellas; Financial Interests, Personal, Advisory Board: Pfizer Hellas; Financial Interests, Personal, Advisory Board: Roche Hellas; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Roche Hellas; Financial Interests, Personal, Other, Travel and Education support: Pfizer Hellas; Financial Interests, Personal, Other, Travel and Education support: Roche Hellas; Financial Interests, Personal, Other, Travel and Education support: MSD Greece; Financial Interests, Personal, Other, Travel and Education support: Roche Hellas; Financial Interests, Personal, Other, Travel and Education support: Astellas Pharma; Financial Interests, Personal, Other, Travel and Education support: Novartis (Hellas); Financial Interests, Personal, Other, Travel and Education support: Pfizer; Financial Interests, Personal, Other, Travel and Education support: Roche; Financial Interests, Personal, Other, Travel and Education support: Enorasis. I. Bozovic-Spasovic: Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: Pfizer.